Imagine a world where a common, long-used medication could turn the tide against one of the most stubborn forms of breast cancer. That’s exactly what researchers at the University of Basel, Switzerland, have uncovered about dexamethasone—a drug traditionally used to ease chemotherapy side effects like nausea and inflammation. But here’s where it gets even more fascinating: this same drug might hold the key to fighting therapy-resistant breast cancer metastases, particularly in estrogen receptor-positive (ER+) cases.
Dexamethasone, a synthetic compound mimicking the body’s stress hormone cortisol, has been a staple in cancer care for its ability to manage treatment side effects. However, a groundbreaking study led by Professor Mohamed Bentires-Alj reveals it could do much more. The team discovered that dexamethasone can target and reduce metastases in ER+ breast cancer, a subtype that often becomes resistant to standard hormone therapies.
ER+ breast cancer typically responds well to anti-hormonal treatments, which aim to deactivate the overactive estrogen receptors fueling tumor growth. But when metastases develop, they can become resistant, leaving patients with limited options. This is where dexamethasone steps in. In mouse trials, the drug significantly reduced liver metastases and extended survival rates. The mechanism? Dexamethasone activates the glucocorticoid receptor, which in turn suppresses the production of the estrogen receptor, effectively stripping cancer cells of their primary growth driver.
Dr. Madhuri Manivannan, the study’s lead author, explains, “By targeting the estrogen receptor, dexamethasone could potentially halt the progression of these resistant tumors.” The findings were further validated using organoids—lab-grown tumor tissues derived from patients—where dexamethasone consistently reduced estrogen receptor levels.
But here’s where it gets controversial: While this discovery is promising, it’s not a one-size-fits-all solution. Dexamethasone’s effects vary dramatically depending on the breast cancer subtype. In 2019, Professor Bentires-Alj’s team reported in Nature that the drug actually promotes metastases in triple-negative breast cancer, a stark contrast to its benefits in ER+ cases. This raises a critical question: How can the same drug have such opposing effects? And what does this mean for personalized cancer treatment?
Dr. Charly Jehanno, who led the research, emphasizes the need for caution: “While dexamethasone shows potential as a direct therapy for certain breast cancers, these results must be confirmed in clinical trials. The loss of estrogen receptors in response to the drug is particularly intriguing, but we need to see how this translates to patients.”
If proven effective, dexamethasone could be repurposed as a powerful tool against therapy-resistant metastases, offering new hope to patients with limited treatment options. But this discovery also underscores the complexity of cancer biology and the importance of tailored therapies.
And this is the part most people miss: The dual nature of dexamethasone—beneficial in one subtype, harmful in another—highlights the need for precision medicine. It’s a reminder that cancer treatment isn’t one-dimensional, and what works for one patient might not work for another.
So, what do you think? Could dexamethasone revolutionize breast cancer treatment, or does its dual nature complicate its potential? Share your thoughts in the comments—let’s spark a conversation about the future of cancer care.
